Lilly rDNA Glucagon Is Second Approved, Could Beat Novo GlucaGen Launch
Executive Summary
Lilly's recombinant DNA-derived glucagon is the second approved by FDA and could become the first to reach the market.
You may also be interested in...
J&J Theory On Blockbusters: They Are Built, Not Born
Pharmaceutical blockbusters are more likely to emerge from an R&D program that downplays commercial forecasts, Johnson & Johnson Worldwide Pharmaceuticals Group Chairman Christine Poon suggested
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011